Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.

Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS.

Leuk Res. 2014 Apr;38(4):443-6. doi: 10.1016/j.leukres.2013.12.010. Epub 2013 Dec 25.

PMID:
24439565
2.

Cladribine in the treatment of acute myeloid leukemia.

Robak T, Wierzbowska A.

Leuk Res. 2014 Apr;38(4):425-7. doi: 10.1016/j.leukres.2014.01.005. Epub 2014 Jan 14. No abstract available.

PMID:
24485872
3.

A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).

Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K; Polish Adult Leukemia Group.

Eur J Haematol. 2003 Sep;71(3):155-62.

PMID:
12930315
4.

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.

Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A; Polish Adult Leukemia Group.

Eur J Haematol. 2008 Feb;80(2):115-26. Epub 2007 Dec 11.

PMID:
18076637
5.
6.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.

PMID:
18571721
7.

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.

Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S; Polish Adult Leukemia Group.

Ann Hematol. 2005 Sep;84(9):557-64. Epub 2005 Apr 27.

PMID:
15856358
8.

Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.

Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS.

Leuk Res. 2011 Mar;35(3):301-4. doi: 10.1016/j.leukres.2010.09.002. Epub 2010 Nov 24.

PMID:
21109304
9.

CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.

Seiter K, Ahmed N, Shaikh A, Baskind P, Liu D.

Leuk Res. 2016 Jul;46:74-8. doi: 10.1016/j.leukres.2016.04.015. Epub 2016 Apr 26.

PMID:
27151544
10.

Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.

Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F.

Onkologie. 2001 Aug;24(4):356-60.

PMID:
11574763
11.

A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.

Ossenkoppele GJ, van der Holt B, Verhoef GE, Daenen SM, Verdonck LF, Sonneveld P, Wijermans PW, van der Lelie J, van Putten WL, Löwenberg B.

Leukemia. 1999 Aug;13(8):1207-13.

PMID:
10450748
12.
13.

Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.

Martin MG, Welch JS, Augustin K, Hladnik L, DiPersio JF, Abboud CN.

Clin Lymphoma Myeloma. 2009 Aug;9(4):298-301. doi: 10.3816/CLM.2009.n.058.

PMID:
19717379
14.

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.

Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.

Ann Hematol. 2004 Aug;83(8):498-503. Epub 2004 May 20.

PMID:
15156346
16.

Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.

Calip GS, Malmgren JA, Lee WJ, Schwartz SM, Kaplan HG.

Breast Cancer Res Treat. 2015 Nov;154(1):133-43. doi: 10.1007/s10549-015-3590-1. Epub 2015 Oct 8.

17.

Salvaging AML with CLAG: novel option, or more of the same?

Wei A, Teh TC.

Leuk Res. 2011 Mar;35(3):297-8. doi: 10.1016/j.leukres.2010.10.015. Epub 2010 Nov 11. No abstract available.

PMID:
21074270
18.

[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].

Duan MH, Zhang Y, Zhang M, Han X, Zhang Y, Yang C, Feng J, Zhang L, Zhang W, Li J, Tian LP, Zhang Y, Zhou DB.

Zhonghua Xue Ye Xue Za Zhi. 2016 Jul;37(7):571-5. doi: 10.3760/cma.j.issn.0253-2727.2016.07.006. Chinese.

PMID:
27535856
20.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90. Epub 2003 Aug 19.

PMID:
12928754

Supplemental Content

Support Center